CNTX Insider Trading
Insider Ownership Percentage: 2.80%
Insider Buying (Last 12 Months): $107,206.40
Insider Selling (Last 12 Months): $0.00
Context Therapeutics Share Price & Price History
Current Price: $0.62
Price Change: ▼ Price Decrease of -0.0296 (-4.54%)
As of 06/13/2025 02:02 PM ET
Context Therapeutics Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
6/9/2025 | Martin A. Lehr | CEO | Buy | 100,000 | $0.70 | $70,000.00 | 920,190 | |
6/6/2025 | Alex C. Levit | Insider | Buy | 20,000 | $0.58 | $11,600.00 | 29,000 | |
6/6/2025 | Jennifer Lynn Minai-Azary | CFO | Buy | 40,010 | $0.64 | $25,606.40 | 80,010 | |
2/21/2023 | Martin A. Lehr | CEO | Buy | 5,823 | $0.84 | $4,891.32 | 159,701 | |
2/13/2023 | Martin A. Lehr | CEO | Buy | 5,606 | $0.87 | $4,877.22 | 153,878 | |
2/6/2023 | Martin A. Lehr | CEO | Buy | 5,040 | $0.97 | $4,888.80 | 148,272 | |
1/30/2023 | Martin A. Lehr | CEO | Buy | 7,027 | $0.70 | $4,918.90 | 143,232 | |
1/23/2023 | Martin A. Lehr | CEO | Buy | 6,839 | $0.72 | $4,924.08 | 136,205 | |
1/17/2023 | Martin A. Lehr | CEO | Buy | 6,783 | $0.74 | $5,019.42 | 129,366 | |
12/16/2022 | Jennifer Lynn Minai-Azary | CFO | Buy | 25,000 | $0.74 | $18,500.00 | 40,000 | |
12/9/2022 | Alex C. Levit | Insider | Buy | 6,000 | $0.85 | $5,100.00 | 9,000 | |
8/19/2022 | Martin A. Lehr | CEO | Buy | 13,000 | $1.85 | $24,050.00 | 102,583 | |
Context Therapeutics Institutional Trading History
Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
---|
5/16/2025 | Ally Bridge Group NY LLC | 1,157,448 | $0.71M | 0.6% | -26.6% | 1.290% |  |
5/15/2025 | Landscape Capital Management L.L.C. | 41,216 | $25K | 0.0% | -54.2% | 0.046% |  |
5/14/2025 | Affinity Asset Advisors LLC | 660,589 | $0.40M | 0.0% | -34.9% | 0.736% |  |
2/17/2025 | Velan Capital Investment Management LP | 90,000 | $94K | 0.1% | -93.0% | 0.120% |  |
2/17/2025 | Shay Capital LLC | 50,000 | $52K | 0.0% | N/A | 0.067% |  |
2/17/2025 | MPM Bioimpact LLC | 14,705,882 | $15.44M | 2.2% | N/A | 19.608% |  |
2/17/2025 | Millennium Management LLC | 178,718 | $0.19M | 0.0% | +24.2% | 0.238% |  |
2/17/2025 | Citadel Advisors LLC | 29,900 | $31K | 0.0% | N/A | 0.040% |  |
2/17/2025 | Allostery Investments LP | 950,166 | $1M | 1.0% | N/A | 1.267% |  |
2/17/2025 | Ally Bridge Group NY LLC | 1,576,762 | $1.66M | 1.4% | -10.3% | 2.102% |  |
2/14/2025 | Jane Street Group LLC | 27,395 | $29K | 0.0% | N/A | 0.037% |  |
2/14/2025 | Northern Trust Corp | 113,565 | $0.12M | 0.0% | -34.2% | 0.151% |  |
2/14/2025 | Blue Owl Capital Holdings LP | 6,357,928 | $6.68M | 1.6% | +17.5% | 8.477% |  |
2/13/2025 | Marshall Wace LLP | 203,286 | $0.21M | 0.0% | N/A | 0.271% |  |
2/13/2025 | Affinity Asset Advisors LLC | 1,015,340 | $1.07M | 0.1% | -23.1% | 1.354% |  |
2/13/2025 | Walleye Capital LLC | 166,306 | $0.18M | 0.0% | +51.7% | 0.222% |  |
2/13/2025 | Renaissance Technologies LLC | 338,435 | $0.36M | 0.0% | +412.8% | 0.451% |  |
2/13/2025 | ADAR1 Capital Management LLC | 351,094 | $0.37M | 0.1% | -6.1% | 0.468% |  |
2/12/2025 | Landscape Capital Management L.L.C. | 90,000 | $94K | 0.0% | N/A | 0.120% |  |
2/12/2025 | Geode Capital Management LLC | 628,729 | $0.66M | 0.0% | +9.2% | 0.838% |  |
2/12/2025 | Franklin Resources Inc. | 4,003,380 | $4.20M | 0.0% | +115.9% | 5.338% |  |
1/17/2025 | Clear Harbor Asset Management LLC | 57,804 | $61K | 0.0% | +60.6% | 0.077% |  |
11/27/2024 | Franklin Resources Inc. | 1,853,988 | $3.69M | 0.0% | N/A | 2.472% |  |
11/16/2024 | Geode Capital Management LLC | 575,899 | $1.13M | 0.0% | -6.8% | 0.768% |  |
11/15/2024 | Y Intercept Hong Kong Ltd | 45,635 | $89K | 0.0% | N/A | 0.061% |  |
11/15/2024 | State Street Corp | 111,907 | $0.22M | 0.0% | +21.5% | 0.149% |  |
11/14/2024 | Ally Bridge Group NY LLC | 1,757,524 | $3.45M | 1.8% | -6.8% | 2.343% |  |
11/13/2024 | Great Point Partners LLC | 6,934,982 | $13.59M | 4.0% | -6.5% | 9.247% |  |
8/20/2024 | Nantahala Capital Management LLC | 1,935,484 | $3.88M | 0.2% | N/A | 2.581% |  |
8/16/2024 | Driehaus Capital Management LLC | 2,258,065 | $4.53M | 0.0% | N/A | 3.011% |  |
8/15/2024 | Blue Owl Capital Holdings LP | 5,161,290 | $10.35M | 2.9% | N/A | 6.882% |  |
8/15/2024 | Affinity Asset Advisors LLC | 1,619,140 | $3.25M | 0.4% | +392.4% | 2.159% |  |
8/14/2024 | Great Point Partners LLC | 7,419,355 | $14.88M | 2.8% | N/A | 9.893% |  |
8/14/2024 | Ally Bridge Group NY LLC | 1,886,232 | $3.78M | 2.3% | +159.8% | 2.515% |  |
8/9/2024 | Renaissance Technologies LLC | 65,200 | $0.13M | 0.0% | +63.4% | 0.087% |  |
5/29/2024 | Opaleye Management Inc. | 1,108,357 | $1.53M | 0.3% | +13.7% | 1.478% |  |
2/15/2024 | Opaleye Management Inc. | 975,000 | $1.10M | 0.3% | N/A | 6.107% |  |
11/15/2023 | Affinity Asset Advisors LLC | 328,817 | $0.50M | 0.1% | +22.9% | 2.059% |  |
8/21/2023 | Affinity Asset Advisors LLC | 267,574 | $0.43M | 0.1% | N/A | 1.675% |  |
7/21/2023 | Clear Harbor Asset Management LLC | 36,000 | $58K | 0.0% | N/A | 0.225% |  |
2/16/2023 | AIGH Capital Management LLC | 1,143,745 | $0.75M | 0.2% | -11.5% | 7.162% |  |
2/14/2023 | swisspartners Ltd. | 180,000 | $0.12M | 0.2% | +111.8% | 1.127% |  |
11/14/2022 | Worth Venture Partners LLC | 322,628 | $0.36M | 0.2% | +8.4% | 2.021% |  |
11/1/2022 | swisspartners Ltd. | 85,000 | $94K | 0.1% | +101.3% | 0.532% |  |
8/13/2022 | Virtu Financial LLC | 46,445 | $98K | 0.0% | N/A | 0.291% |  |
8/12/2022 | Affinity Asset Advisors LLC | 883,654 | $1.87M | 0.8% | +13.6% | 5.535% |  |
5/4/2022 | swisspartners Ltd. | 14,315 | $4.98M | 3.5% | -66.1% | 0.090% |  |
2/14/2022 | Altium Capital Management LP | 493,531 | $1.31M | 0.4% | N/A | 4.501% |  |
2/11/2022 | QCM Cayman Ltd. | 14,041 | $37K | 0.2% | N/A | 0.128% |  |
2/10/2022 | AIGH Capital Management LLC | 762,721 | $2.03M | 0.6% | N/A | 6.955% |  |
2/9/2022 | swisspartners Ltd. | 42,235 | $0.11M | 0.1% | N/A | 0.385% |  |
Data available starting January 2016
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Read More on Context Therapeutics
Volume
104,172 shs
Average Volume
301,537 shs
Market Capitalization
$55.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.86
Who are the company insiders with the largest holdings of Context Therapeutics?
Who are the major institutional investors of Context Therapeutics?
Which major investors are selling Context Therapeutics stock?
In the last quarter, CNTX stock was sold by these institutional investors:
- Ally Bridge Group NY LLC
- Affinity Asset Advisors LLC
- Landscape Capital Management L.L.C.